In Reply We thank the authors of the 2 letters responding to our randomized clinical trial (RCT) comparing mycophenolate mofetil (MMF) and rituximab in the treatment of steroid-dependent nephrotic syndrome (SDNS).1 They provide us the opportunity to further discuss the main finding of our study, specifically the minimum effective dose of MMF in the treatment of complicated nephrotic syndrome. Schreuder et al and Belluzzi et al raised an important point, contesting that previous studies had already established the appropriate dosage of MMF for SDNS.